Member Info for Irontaz

https://youtu.be/sSsme8PVM3c

I agree MGC Pharma is the one to buy, lots of potential and at 5p it's a bargain. DYOR.

Ehsan, top work again fella, I can see how much of a passion you have for this company. Happy Investing.

I just topped up with another 100k. Bought 100k couple of days back. Long term hold.

Was Joe Public allowed to participate in MGC and KNB ipo's? Those were taken up by investors of high net worth and Institions. CBX has been allowed to. If you saw a restaurant full of people eating food, you would want to know what all fuss is about ? CBX is that. Be very careful my fellow investors market is starting to look crowded already.

I've held these since last March and to be honest with You I'm pretty much back to square one. I did think about topping up when they hit £3.50ish but due to lack of funds available couldn't, that would have been a nice rise ! Long term hold for me.

Have you actually tried they're food ?

I think it's based on some factors such as revenue or profit made they also have to be capitalised well to do with the bounce back loan situation.

Hands were tied by the regulator. Max 9c allowed.

The loss was double of what the market estimate was. Not sure which way SP is going to go with this share today.

£1.54 seems to have found a resistance level, if it breaks above that then £1.60+ is achievable. SP in lead up to results next week should give some indication as to which way this one will go. One wonder's how much of it is already baked in and if it beats estimates. Best of luck to all of those holding.

Shingrix which was deemed one of GSK's best selling products was taking a hit due to the Pandemic as he had to be administered face to face by GP Surgery's, Health Centres etc, now that there is a roadmap to reopening, this should help the SP push up over the next 6 months. I have been very surprised the SP has been floundering at these levels, GSK seem to have been targeted by the market for not having a Covid Vaccine, but I think they are done very well to wait it out and come up with one that can also fight against the new Variants as well. DYOR but in my opinion this is a £17+ share, here is hoping that it get's back to these levels again. Long term hold for me. Divi is the Cherry on top.

Anyone who day trades does so with a high degree of risk, yes we want this to shoot to the moon and all be millionaires, but reality is nothing ever goes up in a straight line. this has only been on the market for a little over 2 weeks, like many others have said, what has fundamentally changed ? nothing, I'm holding this for a minimum 12 months before I ever consider doing anything with it. The master sales agreement signed last week I believe makes MGC cashflow positive as breakeven was stated as 5,000 units per month, initial order is 10,000 units with a minimum of 40,000 units per quarter (That's roughly 13,333 units per month) more than 2.5 times breakeven.

Remember this is for a minimum amount, once the product get's out in the market and feedback from end users starts to come back as positive, demand will pick up. If you can't see the potential in this, then you seriously should reconsider if investing in in the stock market is for you. Do your own research. but once this is picked up by the bigger players it's going to start going up. You can't win the lottery if you don't buy a ticket for the draw !

That contract has a minimum amount but has the potential to be so much bigger.

My guess is people are getting they're ducks in line for CBX next week.

Exactly, long term hold. 1 year from now will have given this ample opportunity to go up and plenty more deals to be done.

Quite a few are also in KNB, that's getting a bit of action today after a RNS announcement.

More chance of Liverpool winning the Premier League this season.

I also have KNB, top sliced half my allocation when SP shot up last week. Not that I need prove anything to You.

Yes, but where are the financial numbers to support the deal ? They should have secured a deal with a value worth something.